Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-03
2007-07-03
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S013800, C514S014800, C514S015800, C514S016700, C530S300000, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000, C530S333000, C530S344000, C530S345000
Reexamination Certificate
active
10273975
ABSTRACT:
The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 5998375 (1999-12-01), Thogersen et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6344180 (2002-02-01), Holst et al.
patent: 6548667 (2003-04-01), Park et al.
patent: 6737417 (2004-05-01), Jo et al.
patent: 2002/0019419 (2002-02-01), De Laszlo et al.
patent: 0142146 (1985-05-01), None
patent: 0221025 (1987-05-01), None
patent: 0 955 314 (1999-11-01), None
patent: 2596393 (1987-10-01), None
patent: 2205837 (1988-12-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/12116 (2000-03-01), None
patent: WO 00/34331 (2000-06-01), None
patent: WO 00/34332 (2000-06-01), None
patent: WO 00/28067 (2000-10-01), None
patent: WO 03/033671 (2003-04-01), None
patent: WO 2004/094461 (2004-11-01), None
Ashworth, D.M. et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ashworth, D.M. et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 22, pp. 2745-2748 (1996).
Atherton, E. et al., “The Fluorenylmethoxycarbonyl Amino Protecting Group”, The Peptides: Analysis, Synthesis, Biology, vol. 9, Special Methods in Peptide Synthesis, Part C, Academic Press, Inc., Udenfriend, S. and Meienhofer, J., eds., pp. 1-38 (1987).
Barany, G. et al., “Solid-Phase Peptide Synthesis”, The Peptides: Analysis, Synthesis, Biology, vol. 2, Special Methods in Peptide Synthesis, Part A, Academic Press, Gross, E. and Meienhofer, J., eds., pp. 1-284 (1980).
Biller, S.A. et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, pp. 1-40 (1996).
Burgess, K. et al., “Solid Phase Syntheses of Oligoureas”, J. Am. Chem. Soc., vol. 119, pp. 1556-1564 (1997).
Byrne, M.M. et al., “Inhibitory effects of hyperglycaemia on fed jejunal motility: potential role of hyperinsulinaemia”, European Journal of Clinical Investigation, vol. 28, pp. 72-78 (1998).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (Jun. 1987).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis., etc.”, Journal of the American Chemical Society, vol. 98, No. 5, pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, pp. 11-20 (1999).
Davern, P. et al., “Chemical and Biological Reactivity of Sulfamidopenicillins”, J. Chem. Soc. Perkin Trans., vol. 2, pp. 381-387 (1994).
Fehrentz, J.-A. et al., “An Efficient Synthesis of Optically Active α-(t-Butoxycarbonylamino)-aldehydes from α-Amino Acids”, Synthesis, pp. 676-678 (1983).
Fingl, E. et al., “Introduction”, The Pharmacological Basis of Therapeutics, Fifth Edition, Macmillan Publishing Co., Inc., Goodman, L.S. et al., eds., pp. 1-46 (1975).
Flint, A. et al., “Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans”, J. Clin. Invest., vol. 101, No. 3, pp. 515-520 (1998).
Gennaro, A.R., ed., Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, pp. xv-xvi (1990).
Gennaro, A.R., ed., Remington: Practice of the Science and Pharmacy, 19th Edition, Mack Publishing Company, pp. xv-xvi (1995).
Gennaro, A.R., ed., Remington: Practice of the Science and Pharmacy, 19th Edition, vol. II, Mack Publishing Company, pp. vii-viii (1995).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol. 16, No. 1, pp. 16-30 (1998).
Gutzwiller, J.-P. et al., “Glucagon-like peptide-1: a potent regulator of food intake in humans”, Gut, vol. 44, pp. 81-86 (1999).
Hara, S., “Ileal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24, No. 4, pp. 425-430 (1999).
Holst, J.J., “Glucagon-like Peptide-1, A Gastrointestinal Hormone with a Pharmaceutical Potential”, Current Medicinal Chemistry, vol. 6, pp. 1005-1017 (1999).
Johannsson, G. et al., “Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure”, Journal of Clinial Endocrinology and Metabolism, vol. 82, No. 3, pp. 727-734 (1997).
King, D.S. et al., “A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis”, Int. J. Peptide Protein Res., vol. 36, pp.
Bastos Margarita M.
Bernatowicz Michael
Ewing William R.
Lee Ving
Mapelli Claudio
Bristol--Myers Squibb Company
Carey Brian C.
Kosar Andrew D.
Tsang Cecilia J.
LandOfFree
Human glucagon-like-peptide-1 mimics and their use in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human glucagon-like-peptide-1 mimics and their use in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human glucagon-like-peptide-1 mimics and their use in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784160